http://www.pharmaceuticalsinsight.com Pharmaceuticals & Healthcare Insight RSS Feed from Business Monitor International en Copyright 2010, Business Monitor International Ltd Thu, 04 Mar 2010 06:30 GMT Thu, 04 Mar 2010 06:30 GMT AFP RSS Generator We expect the Moroccan healthcare market to increase in value from US$4.9bn in 2009 to US$6.6bn by 2014, representing a compound annual growth rate (CAGR) of 6.05% in US dollar terms and 8.2% in local currency. Per-capita spending on healthcare will be US$196 by 2014, while public sector expenditure in this segment will be 1.9bn - accounting for just 29% of all healthcare http://www.pharmaceuticalsinsight.com/file/86726/Healthcare-Expenditure-To-Reach-US$6-6bn-By-2014.html Wed, 03 Mar 2010 00:00 GMT Aligning Russian pharmaceutical manufacturing with international standards is an essential measure if the country is to build a domestic industry capable of competing with more developed multinational companies. The transition to enforced Good Manufacturing Practice (GMP) for domestic drugmakers has been repeatedly delayed, with firms reluctant to make expensive initial investment and incur the consequent increases in long-term running costs. However, BMI believes developments in 2010 may see an acceleration in introducing mandatory GMP, although we caution that significant state support would be required to implement these changes in the short- to http://www.pharmaceuticalsinsight.com/file/86725/Small-Steps-Towards-GMP-Compliance.html Wed, 03 Mar 2010 00:00 GMT Sticking to its slogan 'Asda: Saving You Money Everyday', leading UK retailer Asda is to offer patients fertility drugs at a not-for-profit basis in its in-store pharmacies. The supermarket aims to establish itself as the most competitive pharmacy network in the UK - reinforcing BMI's Pharmaceuticals & Healthcare service's newest long-term core view that non-healthcare companies will increasingly enter the medical services sector. Companies see medical services as a sustainable and expanding business, principally because people will always get sick and the global population is both growing and ageing. Unlike other industries, the sector is resilient to economic downturns, as http://www.pharmaceuticalsinsight.com/file/86724/Asda-To-Offer-Cheaper-IVF-Drugs.html Wed, 03 Mar 2010 00:00 GMT Despite a compound annual growth rate (CAGR) of 1.26% in local currency terms and 3.71% in US dollar terms from 2004-2009, BMI's outlook for the French drug market is less optimistic over the next five years. From 2009-2014, a CAGR of -1.41% is projected in local currency terms (-3.50% in US dollar terms), largely as a result of the impending patent cliff and the consequent consumption of lower-value generic drugs in place of the high-value patented drugs. BMI calculates that drug sales in France reached EUR30.25bn (US$42.61bn) in 2009. It is expected that 2010 drug sales will reach EUR30.49bn (US$42.94bn), http://www.pharmaceuticalsinsight.com/file/86722/Patent-Cliff-To-Cause-A-Decline-Drug-Market-Value.html Wed, 03 Mar 2010 00:00 GMT The race to buy Ratiopharm is nearing an end with Pfizer, Teva and Actavis still in the running. The firms have requested access to sensitive information and audited accounts which will be available later this month. In a new twist, the Swedish private equity group EQT Partners, which had been backing Actavis, has withdrawn its support. Despite this, Actavis is still in the final bidding round for Ratiopharm, reflecting its past strategy of growth through acquisitions before it went private. http://www.pharmaceuticalsinsight.com/file/86723/Ratiopharm-Deal-Edging-Closer.html Wed, 03 Mar 2010 00:00 GMT BMI is maintaining its forecast for the Philippines pharmaceutical market despite another round of medicine price cuts. The Department of Health expects the lower prices of 97 preparations to result in private sector savings of PHP1bn (US$21.7mn). This reduced spending accounts for only 0.87% of the PHP119bn (US$2.50bn) pharmaceutical market and will therefore have no significant effect on our 5-year and 10-year sales projections. http://www.pharmaceuticalsinsight.com/file/86671/More-Medicine-Price-Cuts-Unveiled.html Tue, 02 Mar 2010 00:00 GMT South Africa's largest drugmakers have responded positively to the new trade policy that will lower antiretroviral (ARV) medicine prices in the country. Local manufacturers will be able to lower prices to match those of importers, enabling them to be more competitive and in turn increasing the availability, value and choice of generic medicines on the market. South Africa has one of the highest HIV/AIDs prevalence rates in the world and therefore this policy will have immediate and far reaching impact on both pharmaceutical market spending and later, the productivity of the labour force. http://www.pharmaceuticalsinsight.com/file/86669/New-Policy-To-Affect-Pharmaceutical-Trade.html Tue, 02 Mar 2010 00:00 GMT We expect pharmaceutical spending in Morocco to increase from US$1.4bn in 2009 to US$1.6bn in 2014, at a slow compound annual growth rate (CAGR) of 2.38%. By 2014, prescription medicines will comprise 72% of the total market at a value of US$1.17bn and will continue to rise, comprising 83% by 2019. http://www.pharmaceuticalsinsight.com/file/86670/Pharmaceutical-Market-Summary.html Tue, 02 Mar 2010 00:00 GMT The US Food and Drug Administration (FDA) and the National Institutes of Health (NIH) are to work together to accelerate the availability of innovative medicines. As illustrated by FDA data, the mean review times for marketing authorisations have varied considerably over recent years, from 6 months in 2001 to approximately 15 months in 2005. BMI believes that any efforts made by the FDA to facilitate new product launches will be welcomed both by patients and the pharmaceutical industry - the quicker a medicine is made available to a patient after completion of clinical trials, the quicker a drug company can start http://www.pharmaceuticalsinsight.com/file/86668/FDA-NIH-Partnership-To-Accelerate-Drug-Approvals.html Tue, 02 Mar 2010 00:00 GMT In February 2010, the Belgian Association of Clinical Research Professionals (ACRP.be), the Belgian Association of Pharmaceutical Physicians (BeAPP), the Belgian Association of Phase 1 Units (Bapu), the Federal Agency for Medicines and Health Products (FAGG/AFMPS) and pharma.be, the association of drugmakers, launched an initiative to promote Belgium as a location in which to conduct clinical trials. BMI welcomes this development. It reinforces our view that Belgium's medical authorities have recognised the importance of promoting the country as an important base for http://www.pharmaceuticalsinsight.com/file/86667/Agencies-To-Work-To-Promote-Clinical-Trials-Environment.html Tue, 02 Mar 2010 00:00 GMT Denmark-based pharmaceutical company Lundbeck has expanded its agreement with Israel-based partner Teva. The Danish drugmaker will sell Parkinson's disease drug Azilect (rasagline) in six Asian markets: China, South Korea, Hong Kong, Malaysia, Thailand and the Philippines. The full financial terms of deal have not been revealed, but Lundback will pay a share of net sales in the markets to http://www.pharmaceuticalsinsight.com/file/86621/Lundbeck-Eyes-Asian-Markets.html Fri, 26 Feb 2010 00:00 GMT BMI calculates that France's health expenditure reached a value of EUR220.0bn (US$309.9bn) in 2009. In 2010 we expect it to rise to EUR226.0bn (US$318.3bn), and by 2014, healthcare spending is forecast at EUR246.0bn (US$311.4), equating to a 2.26% compound annual growth rate (CAGR) in euro terms and 0.10% in US dollar terms. Expenditure as a percentage of GDP is high, at 11.5% in 2009, and annual per capita expenditure is US$4,826, which is in line with per capita expenditure in other G7 http://www.pharmaceuticalsinsight.com/file/86619/Government-Seeks-To-Contain-Healthcare-Costs.html Fri, 26 Feb 2010 00:00 GMT Despite achieving a net profit of US$208mn in Q409, up by 44% from Q408, German drugmaker Bayer has posted full-year 2009 sales of US$42.47bn, a 5.3% decline in revenues from the US$44.86bn earned in the previous year. The company also recorded a 20.9% decline in net income to US$1.85bn. The company missed its target of restricting the decline in earnings before interest, taxes, depreciation and amortisation (EBITDA) before special items to 5%, with EBITDA falling 6.6% during the year to US$8.82bn. Charges related to the integration of Schering, restructuring measures and litigation costs reduced earnings by US$1.04bn in http://www.pharmaceuticalsinsight.com/file/86620/Healthcare-Division-Sales-Aid-Bayer-Financial-Results.html Mon, 01 Mar 2010 00:00 GMT Patented drugs prices in Canada have to be approved by 19 bodies, including 17 provincial ones. The Common Drug Review and the federal Patented Medicines Review Board (PMRB) are the major governmental bodies in this process. The protracted and complex approvals process can hinder access to new and innovative medicines, and streamlining will ultimately be necessary. However, we believe that the decentralised nature of the pricing strategy is unlikely to change. http://www.pharmaceuticalsinsight.com/file/86616/Pricing-And-Reimbursement-Overview.html Fri, 26 Feb 2010 00:00 GMT US based Perrigo has released its Q210 results, which show an increase in total sales of all segments, giving an overall 8.56% sales increase year-on-year (y-o-y). While its prescription drug segment had the highest growth, at 37% y-o-y, the consumer healthcare segment will continue to account for the majority of the firm's revenues. http://www.pharmaceuticalsinsight.com/file/86617/Perrigo-Releases-Positive-Q210-Results.html Fri, 26 Feb 2010 00:00 GMT